Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
暂无分享,去创建一个
W. Scheithauer | F. di Costanzo | M. Palmer | C. Köhne | P. Rougier | D. Cunningham | P. Schöffski | B. Glimelius | B. Baron | F. Pignatti | H. Hecker | E. Aranda | G. Blijham | J. Wils | F. D. Costanzo | S. Micheel | C. Köhne | H. Hecker | D. Cunningham | C.-H. Köhne
[1] J P Pignon,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[2] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[3] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Jonker,et al. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials , 2000, British Journal of Cancer.
[5] Daniel S. Miller,et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.
[6] S. Groshen,et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] B. Dörken,et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Christian Jacques,et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.
[10] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[11] D. Kerr,et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Köhne,et al. First-Line Chemotherapy for Colorectal Carcinoma – We are Making Progress , 1998, Oncology Research and Treatment.
[13] C. Boni,et al. High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. , 1998, American journal of clinical oncology.
[14] A. Carrato,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] C. Helmers,et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Hiddemann,et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Ducreux,et al. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. , 1997, European Journal of Cancer.
[18] A. Padhani,et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] W. Scheithauer,et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Blijham,et al. Double modulation of high-dose 5-fluorouracil with low-dose PALA and methotrexate: results of a randomized EORTC study , 1997 .
[21] W. Hiddemann,et al. Phase II Evaluation of 5-Fluorouracil plus Folonic Acid and Alpha 2b-lnterferon in Metastatic Colorectal Cancer , 1997 .
[22] L. Collette,et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Pavlidis,et al. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. , 1996, Medical and pediatric oncology.
[24] F. Costanzo,et al. 721 Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2B (IFN) in advanced colorectal cancer (ACRC): A randomized trial of the italian oncology group for clinical research (GOIRC) , 1995 .
[25] D. Kerr,et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. , 1995, European journal of cancer.
[26] T. Hickish,et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Norman,et al. The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer , 1995 .
[28] A. Norman,et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] W. Hiddemann,et al. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Z Lou,et al. Tree-structured prediction for censored survival data and the Cox model. , 1995, Journal of clinical epidemiology.
[31] A. Norman,et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] S. Meijer,et al. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Påhlman,et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. , 1994, British Journal of Cancer.
[34] L. Påhlman,et al. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. , 1994, European journal of cancer.
[35] B. Glimelius. Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] C. Boni,et al. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Erlichman,et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. , 1992, European journal of cancer.
[39] L. Påhlman,et al. Determinants of prognosis in advanced colorectal cancer. , 1991, European journal of cancer.
[40] Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Brummer,et al. Prognostic factors of advanced colorectal cancer patients. , 1986, European journal of cancer & clinical oncology.
[42] S. Steinberg,et al. Prognostic indicators of colon tumors. The gastrointestinal tumor study group experience , 1986, Cancer.
[43] N. Kemeny,et al. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. , 1983, The American journal of medicine.
[44] P. Lavin,et al. Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An eastern cooperative oncology group report , 1980, Cancer.
[45] D.,et al. Regression Models and Life-Tables , 2022 .